|Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP||Pres, CEO, Principal Financial Officer & Director||819.75k||N/A||1962|
|Dr. Leslie Sloan Ph.D.||Chief Operating Officer||538.35k||N/A||1971|
|Mr. Steven Weber||VP, Principal Accounting Officer & Corp. Controller||N/A||N/A||1977|
|Joey Perrone||Sr. Director of Fin. & Investor Relations||N/A||N/A||N/A|
|Kelly Boothe Ph.D.||Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Eugene Sackett||VP of HR||N/A||N/A||N/A|
|Mr. Michael C. Hanley M.B.A.||Chief Commercial Officer||N/A||N/A||1973|
|Dr. Eric Bradford M.B.A., M.D., M.Sc.||Chief Devel. Officer||N/A||N/A||N/A|
|Dr. Scott W. Rowlinson||VP of Research||N/A||N/A||1968|
|Dr. F. Andrew Dorr||Exec. Officer||N/A||N/A||1953|
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Aeglea BioTherapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.